SciClone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life-threatening diseases. The company s primary objective is to develop and market its lead drug candidate, Zadaxin, which is designed for the treatment of hepatitis C, hepatitis B and certain cancers. Though it has yet to secure approvals in the United States or Europe, the drug is for sale in more than 30 countries internationally and generated $22 million in revenues in 2004. China is the drug s most active market, accounting for more than 90 percent of its sales. SciClone s other proprietary compound in development is SCV-07, which is meant for the treatment of viral and infectious diseases. SciClone Pharmaceuticals is based in San Mateo, Calif.